Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EBITDA (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed EBITDA for 7 consecutive years, with -$14.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 6.47% year-over-year to -$14.8 million, compared with a TTM value of -$77.6 million through Dec 2025, down 14.3%, and an annual FY2025 reading of -$77.6 million, down 14.3% over the prior year.
  • EBITDA was -$14.8 million for Q4 2025 at aTYR PHARMA, up from -$26.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.2 million in Q1 2021 and bottomed at -$26.7 million in Q3 2025.
  • Average EBITDA over 5 years is -$14.0 million, with a median of -$13.5 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 485.64% in 2021, then grew 7.99% in 2022.
  • Year by year, EBITDA stood at -$8.6 million in 2021, then grew by 7.99% to -$8.0 million in 2022, then tumbled by 100.74% to -$16.0 million in 2023, then rose by 0.87% to -$15.8 million in 2024, then rose by 6.47% to -$14.8 million in 2025.
  • Business Quant data shows EBITDA for ATYR at -$14.8 million in Q4 2025, -$26.7 million in Q3 2025, and -$20.3 million in Q2 2025.